Mediterranean Journal of Hematology and Infectious Diseases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Adverse pregnancy outcomes in sickle cell trait: a prospective cohort study evaluating clinical and haematological parameters in postpartum mothers and new-borns.
Conclusions –The study revealed that SCT is associated with adverse pregnancy outcomes, including maternal and neonatal anaemia, low birth weight and increased risk of still birth, miscarriage and admission to SCBU. Therefore, pregnant women with SCT should be regarded as a high-risk group, and given pre-conceptual advice and multidisciplinary antenatal and postnatal care. (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - December 31, 2022 Category: Hematology Authors: r. Salam Al-Kindi Source Type: research

Better outcome of high-dose ceftazidime in hemato – oncological patients with infections caused by extensively drug-resistant pseudomonas aeruginosa
Conclusion: Ceftazidime in high doses is a very potent ATB for the treatment of XDRP. aeruginosa infections in neutropenic cancer with acceptable toxicity. (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - December 31, 2022 Category: Hematology Authors: Alzbeta Zavrelova, Jakub Radocha, Pavla Paterova, Pavel Zak, Benjamin Visek, Martin Sima Source Type: research

Management of latent tuberculosis infection based on t-spot.tb assay in patients with hematological malignancies
Conclusions:INH treatment was generally well tolerated, and serious drug-related side effects were observed infrequently. Although LTBI cannot be demonstrated in patients with HIV(+) HM who are scheduled for chemotherapy, these patients should be closely monitored for the development of active TB infection.Keywords: Hematologic malignancies, Interferon-Gamma Release Assays, Latent tuberculosis (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - December 31, 2022 Category: Hematology Authors: Emrah Kiliacaslan, Kadir Canoglu Source Type: research

Samir Ballas Obituary
no abstract (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 30, 2022 Category: Hematology Authors: Giuseppe G.M. Leone Source Type: research

Treatment of advanced systemic mastocytosis with midostaurin: practical guidance for optimal therapy and management
Systemic mastocytosis (SM) is a rare disease with a range of clinical presentations, and the vast majority of patients have aKIT D816V mutation that results in gain of function. The multikinase/KIT inhibitor midostaurin inhibits the D816V mutant, and has a well-established role in treatment of advanced SM. Even if considered the standard of therapy, some open questions remain on how to optimize the management of midostaurin in daily practice. The current review presents the opinions of a group of experts who met to discuss routine practice with the use of midostaurin in patients with advanced SM. The efficacy and safety of...
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 29, 2022 Category: Hematology Authors: Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni Source Type: research

The growing role of the bh3 mimetic drug venetoclax in the therapy of acute myeloid leukemia
In spite recent progresses, acute myeloid leukemia (AML) remains a disease associated with poor prognosis, particularly in older AML patients unfit to tolerate intensive chemotherapy treatment. The development and introduction in therapy of the drug Venetoclax, a potent BH3 mimetic targeting the antiaopoptotic protein BCL-2, inducing apoptosis of leukemic cells, has shown to be a promising treatment for newly diagnosed, relapsed and refractory AML patients ineligible for induction chemotherapy. Combination treatments using Ventoclax and a hypomethylating agent (azacytidine or decitabine) or low-intensity chemotherapy have ...
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 29, 2022 Category: Hematology Authors: Elvira Pelosi, Dr. Germana Castelli, Ugo Testa Source Type: research

Covid-19; Cholera and Crimean-Congo hemorrhagic fever in Iraq: A country with three outbreaks
NA (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 29, 2022 Category: Hematology Authors: Nawfal R Hussein Source Type: research

Monocyte HLA-Dr Expression to Monitor Immune Response and Potential Infection Risks Following Vaso-Occlusive Crises in Patients with Sickle Cell Anemia
No abstract required for a scientific letter (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 29, 2022 Category: Hematology Authors: Romain Fort, Guillaume Monneret, Elie Nader, Giovanna Cannas, Philippe Connes, Fabienne Venet, Arnaud Hot Source Type: research

The possible role of chronic infection in the etiopathogenesis of a case of 5q-syndrome associated with tuberculosis and abnormality of the X chromosome.
(Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 29, 2022 Category: Hematology Authors: Lubomir Mitev Source Type: research

KIR2DL2, KIR2DL5A and KIR2DL5B genes induce susceptibility to dengue virus infection while KIR3DL3 and KIR2DS5 confers protection
Conclusion: The results suggest a contribution ofKIR2DL2, KIR2DL5Aand KIR2DL5Bgenes in the susceptibility of DF development. While,KIR3DL3 andKIR2DS5were found to be associated with protection against DF development by enhancing both the innate and acquired immune responses. (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 29, 2022 Category: Hematology Authors: Aziz Sidi Aristide TAPSOBA, Florencia Wendkuuni Djigma, Bagora BAYALA, Pegdwend é Abel SORGHO, Lassina TRAORE, Théodora Mahoukèdè ZOHONCON, Shoukrat Ohuwa Toyin BELLO, Prosper BADO, Bapio Valérie Elvira Jean Télesphore BAZIE, Fiffou YOUGBAR Source Type: research

Impact of covid-19 on outcomes of patients with hematologic malignancies: a multi-center, retrospective study
Conclusions: In patients with hematologic malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Cardiac diseases, cytotoxic chemotherapy, lymphopenia, thrombocytopenia, and high CRP are the independent risk factors for mortality in hematologic malignancy patients with COVID-19.Keywords: Covid; Hematologic Malignancy; Cytotoxic chemotherapy. (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 29, 2022 Category: Hematology Authors: İbrahim Halil Açar, Sebnem Izmir Güner , Muzeyyen Aslaner Ak, Mesut Gocer, Erman Ozturk , Figen Atalay, Gulden Sincan , Aysun Senturk Yikilmaz, Omer Ekinci, Idris Ince, Emine Gulturk , Nazli Demir, Ali Dogan, Yildiz Ipek, Birol Guvenc Source Type: research

Detection of antinuclear antibodies targeting intracellular signal transduction, metabolism, apoptotic processes and cell death in critical covid-19 patients
Conclusion: Our results further support the notion of routine screening for autoimmune responses in COVID-19 patients, which might help improve disease prognosis and patient management. Further, results provide compelling evidence that ANA-positive individuals should be excluded from being donors for convalescent plasma therapy in the context of COVID-19. (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 29, 2022 Category: Hematology Authors: HADI YASSINE Source Type: research

Clinical characteristics and prognostic factors in primary breast diffuse large b-cell lymphoma
ConclusionIn our cohort, PB-DLBCL clinical features are similar to prior literature reports. Stage-modified IPI score and CNS relapse were associated with overall survival. (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - August 27, 2022 Category: Hematology Authors: guangliang Chen, Dou-dou Li, Sufen Sufen, Shiyu Jiang, Qunling Zhang, jia jin, Zuguang Xia, Yizhen Liu, Xiaojian Liu, Yanzhe Zhu, Yu Chen, Lingli Gu, Xiaonan Hong, Junning Cao, Rong Tao, Fangfang Lv Source Type: research